Prognostic analysis reveals poor clinical outcomes with elevated caveolin-1 in triple-negative breast cancer, highlighting its potential utility as an independent biomarker.
Currently, there are few treatment-predictive and prognostic biomarkers in triple-negative breast cancer (TNBC). Caveolin-1 (CAV1) is linked to chemoresistance and several important processes involved in tumor progression and metastasis, such as epithelial-mesenchymal transition (EMT). Herein, we report that high CAV1 gene expression is an independent factor of poor prognosis in TNBC.
No takes yet. Share an insight, caveat, or question.
Godina et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: